SCHEMBL52166

SCHEMBL52166

Nc1nc2c(ncn2C2OC3COP(=O)(O)OC3C2O)c(=O)[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
STING1 Q86WV6 18/20 1.00
PDE3B Q13370 1/20 1.00
PDE3A Q14432 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12671632 1.00 STING1 (1.00) STING1PDE3BPDE3A
SCHEMBL17974376 1.00 STING1 (1.00) STING1PDE3BPDE3A
SCHEMBL12634565 1.00 STING1 (1.00) STING1PDE3BPDE3A
SCHEMBL17325408 1.00 STING1 (1.00) STING1PDE3BPDE3A
SCHEMBL12634582 1.00 STING1 (1.00) STING1PDE3BPDE3A
SCHEMBL18737202 1.00 STING1 (1.00) STING1PDE3BPDE3A
SCHEMBL24467522 1.00 STING1 (1.00) STING1PDE3BPDE3A
SCHEMBL738 1.00 STING1 (1.00) STING1PDE3BPDE3A
SCHEMBL21470181 1.00 STING1 (1.00) STING1PDE3BPDE3A
SCHEMBL21498373 1.00 STING1 (1.00) STING1PDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 8724 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680215-A1 COMPOSITIONS AND METHODS FOR AMELIORATING ADVERSE EFFECTS OF THERAPIES MDX Management LLC (US) 2026-01-21 EP claimed
EP-4593847-A1 INHIBITION OF GENOTOXIC STRESS TO IMPROVE T CELL ENGINEERING GENENTECH, INC. (US) 2025-08-06 EP claimed
WO-2025076210-A1 CHLAMYDIA VACCINE COMPOSITIONS VAXCYTE, INC. (US) 2025-04-10 WO claimed
US-20250099622-A1 COMPOSITIONS AND METHODS FOR EXPRESSING THERAPEUTICS Avirmax Biopharma Inc. 2025-03-27 US claimed
WO-2025015182-A2 COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNITY NEW YORK SOCIETY FOR THE RELIEF OF THE RUPTURED AND CRIPPLED, MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY (US) 2025-01-16 WO claimed
EP-4490300-A1 COMPOSITIONS AND METHODS FOR EXPRESSING THERAPEUTICS Avirmax Biopharma Inc. (US) 2025-01-15 EP claimed
CN-119256089-A Compositions and methods for expressing therapeutic agents 阿维麦克思生物制药公司 2025-01-03 CN claimed
CN-119074933-A Novel strategy for delivering cGAMP molecules 海南大学 2024-12-06 CN claimed
WO-2024196822-A1 COMPOSITIONS AND METHODS FOR AMELIORATING ADVERSE EFFECTS OF THERAPIES MDX MANAGEMENT LLC (US) 2024-09-26 WO claimed
EP-4433599-A1 SPHERICAL NUCLEIC ACIDS FOR CGAS-STING AND STAT3 PATHWAY MODULATION FOR THE IMMUNOTHERAPEUTIC TREATMENT OF CANCER Northwestern University (US) 2024-09-25 EP claimed
WO-1994022855-A1 NITROGEN-CONTAINING FUSED-HETEROCYCLE COMPOUNDS EISAI CO., LTD. (JP) 1994-10-13 WO claimed
WO-1994013278-A1 METHODS FOR TREATMENT WITH DIMERCAPTOSUCCINIC ACID (DMSA) CEDARS-SINAI MEDICAL CENTER (US) 1994-06-23 WO claimed
EP-0535216-A1 DNA ENCODING MAMMALIAN PHOSPHODIESTERASES THE BOARD OF REGENTS OF THE UNIVERSITY OF WASHINGTON (US) 1993-04-07 EP claimed
WO-1992018541-A1 DNA ENCODING MAMMALIAN PHOSPHODIESTERASES THE BOARD OF REGENTS OF THE UNIVERSITY OF WASHINGTON (US) 1992-10-29 WO claimed
EP-0493444-A1 BLOOD-BRAIN BARRIER MODEL ATHENA NEUROSCIENCES, INC. (US) 1992-07-08 EP claimed
EP-0234854-B1 USE OF PHOSPHODIESTERASE INHIBITORS AND CYCLIC NUCLEOTIDE ANALOGUES FOR THE MANUFACTURE OF A MEDICAMENT FOR STIMULATING TEAR SECRETION EYE RESEARCH INSTITUTE OF RETINA FOUNDATION (US) 1991-05-08 EP claimed
WO-1991005038-A1 BLOOD-BRAIN BARRIER MODEL ATHENA NEUROSCIENCES, INC. (US) 1991-04-18 WO claimed
EP-0406210-A2 Ophthalmic composition WASHINGTON UNIVERSITY (US) 1991-01-02 EP claimed
US-4885301-A Purinone derivatives which have bronchodilator, vasodilator and anti-allergic activities SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1989-12-05 US claimed
EP-0234854-A2 Use of phosphodiesterase inhibitors and cyclic nucleotide analogues for the manufacture of a medicament for stimulating tear secretion EYE RESEARCH INSTITUTE OF RETINA FOUNDATION (US) 1987-09-02 EP claimed